Medicine Description synjardy 12.5/1000mg
synjardy 12.5/1000mg tablets is a medication that combines empagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Empagliflozin works by inhibiting the sodium-glucose co-transporter 2 in the proximal renal tubules. This mechanism reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and consequently lowering blood glucose levels. Metformin complements this effect by decreasing hepatic glucose production, enhancing insulin sensitivity, and promoting glucose uptake in peripheral tissues. Together, they provide a multifaceted approach to managing hyperglycemia in patients with type 2 diabetes.
Indications and Uses of synjardy 12.5/1000mg tablets
- Management of blood glucose levels in adults with type 2 diabetes mellitus
- Used as an adjunct to diet and exercise to improve glycemic control
- May be utilized in patients with cardiovascular disease to improve life quality
Side Effects of synjardy 12.5/1000mg tablets
- Gastrointestinal disturbances, including nausea and diarrhea
- Increased risk of urinary tract infections
- Potential for dehydration and hypotension
- Rarely, lactic acidosis may occur
Storage and Handling
Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
Patient Advice and Precautions
Patients should be educated about the importance of adhering to prescribed dietary and exercise regimens. Regular monitoring of blood glucose levels is essential. Inform healthcare providers of any adverse effects and ensure a thorough review of medications to prevent interactions. Hydration should be maintained to reduce the risk of side effects.